NetworkNewsBreaks – Fortress Biotech, Inc. (NASDAQ: FBIO) Featured in ROTH Equity Research Report
Fortress Biotech (NASDAQ: FBIO) was featured in a recent Equity Research Report published by ROTH Capital Partners, LLC. The report reads, “This is a weekly update tracking prescriptions for FBIO's Ximino launch (extended release minocycline capsule for the treatment of acne). Total prescriptions decreased to 2,083 from 2,365 last week. Overall, we viewed this week's data as noise given the Martin Luther King Jr. holiday celebrated on January 20th. Maintain Buy rating with a price target of $4.00/share.” To request access to the full report, visit http://nnw.fm/DXCr3 About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that…







